Johanna Friedl-Naderer
Direktor/Vorstandsmitglied bei Biogen Idec Ltd.
Vermögen: 160 367 $ am 30.04.2024
Profil
Johanna Friedl-Naderer is currently a Director at Biogen Idec Ltd.
She previously held Director positions at the International Federation of Pharmaceutical Manufacturers, Swiss-American Chamber of Commerce, European Federation of Pharmaceutical Industries & Assns, and Interpharma.
Prior to her current role, she was the President-Europe, Canada & Partner Markets at Biogen, Inc. from 2001 to 2022.
She is currently the Chief Operating Officer & Executive Vice President at Vir Biotechnology, Inc. from 2022 to 2023.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
VIR BIOTECHNOLOGY, INC.
0,02% | 03.04.2023 | 21 018 ( 0,02% ) | 160 367 $ | 30.04.2024 |
Aktive Positionen von Johanna Friedl-Naderer
Unternehmen | Position | Beginn |
---|---|---|
Biogen Idec Ltd.
Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | Direktor/Vorstandsmitglied | 04.12.2014 |
Ehemalige bekannte Positionen von Johanna Friedl-Naderer
Unternehmen | Position | Ende |
---|---|---|
VIR BIOTECHNOLOGY, INC. | Geschäftsführer | 29.09.2023 |
BIOGEN INC. | Corporate Officer/Principal | 01.01.2022 |
International Federation of Pharmaceutical Manufacturers
International Federation of Pharmaceutical Manufacturers BiotechnologyHealth Technology The International Federation of Pharmaceutical Manufacturers and Traders is a global organization that promotes technology transfer in the pharmaceutical industry. The non-profit company is based in Geneva, Switzerland. The Swiss company believes that technology transfer helps bridge research and development gaps, increases the availability of vaccines and medicines, and stimulates investment in key industrial areas. David Reddy has been the CEO of the company since 2024. | Direktor/Vorstandsmitglied | - |
Interpharma
Interpharma Miscellaneous Commercial ServicesCommercial Services Interpharma operates as an association of research-based pharmaceutical companies in Switzerland. It provides information on the pharmaceuticals market, healthcare system, and biomedical research. The company is headquartered in Basel, Switzerland. | Direktor/Vorstandsmitglied | - |
Swiss-American Chamber of Commerce
Swiss-American Chamber of Commerce Miscellaneous Commercial ServicesCommercial Services Swiss-American Chamber of Commerce is an organization that advocates for Swiss, American, and multinational business interests. The non-profit company is based in Zurich, Switzerland. The Swiss company is active in all three major regions of Switzerland, organizing events and conducting comprehensive studies on business-related topics. The organization's special committees provide valuable input into its operations, and its flagship publication, the Yearbook, contains a member directory and a comprehensive collection of facts and figures on Swiss-U.S. business relations. Martin M. Naville has been the CEO of the company since 2004. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
VIR BIOTECHNOLOGY, INC. | Health Technology |
BIOGEN INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Biogen Idec Ltd.
Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
European Federation of Pharmaceutical Industries & Assns
European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Commercial Services |
Swiss-American Chamber of Commerce
Swiss-American Chamber of Commerce Miscellaneous Commercial ServicesCommercial Services Swiss-American Chamber of Commerce is an organization that advocates for Swiss, American, and multinational business interests. The non-profit company is based in Zurich, Switzerland. The Swiss company is active in all three major regions of Switzerland, organizing events and conducting comprehensive studies on business-related topics. The organization's special committees provide valuable input into its operations, and its flagship publication, the Yearbook, contains a member directory and a comprehensive collection of facts and figures on Swiss-U.S. business relations. Martin M. Naville has been the CEO of the company since 2004. | Commercial Services |
Interpharma
Interpharma Miscellaneous Commercial ServicesCommercial Services Interpharma operates as an association of research-based pharmaceutical companies in Switzerland. It provides information on the pharmaceuticals market, healthcare system, and biomedical research. The company is headquartered in Basel, Switzerland. | Commercial Services |
International Federation of Pharmaceutical Manufacturers
International Federation of Pharmaceutical Manufacturers BiotechnologyHealth Technology The International Federation of Pharmaceutical Manufacturers and Traders is a global organization that promotes technology transfer in the pharmaceutical industry. The non-profit company is based in Geneva, Switzerland. The Swiss company believes that technology transfer helps bridge research and development gaps, increases the availability of vaccines and medicines, and stimulates investment in key industrial areas. David Reddy has been the CEO of the company since 2024. | Health Technology |